Imaginab, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.imaginab.com
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
CD8 Minibody Repeatability Study
- Conditions
- MelanomaRenal Cell Carcinoma
- Interventions
- Biological: Zirconium 89Zr crefmirlimab berdoxam
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05744128
- Locations
- 🇬🇧
Castle Hill Hospital, Hull, United Kingdom
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
- Conditions
- Renal Cell CarcinomaMelanomaMerkel Cell Carcinoma, UnspecifiedNon Small Cell Lung Cancer
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05013099
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Providence Saint John's Cancer Institute, Santa Monica, California, United States
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorsPositron-Emission Tomography
- Interventions
- Drug: ⁸⁹Zr-Df-IAB22M2C
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03802123
- Locations
- 🇺🇸
University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
- Conditions
- Hodgkin LymphomaMetastatic Solid MalignanciesPositron-Emission TomographyImmunomodulation
- Interventions
- Drug: ⁸⁹Zr-Df-IAB22M2C Infusion
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03107663
- Locations
- 🇺🇸
Honor Health and Imaging Endpoints, Scottsdale, Arizona, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- ImaginAb, Inc.
- Registration Number
- NCT02424513
- Locations
- 🇺🇸
Washington University, St Louis, Missouri, United States
- Prev
- 1
- 2
- Next